Pharmahungary Group and Remembrane developed and validated a medium throughput in vitro screening platform for testing potential cardiocytoprotective drug candidates against ischemia/reperfusion injury in the presence of hypercholesterolemia/metabolic disease comorbidities.
Further information here
The main purpose of HBA is to strengthen the position of biotechnology as a strategic industry in Hungary.
In each year HBA organizes special forums which provide opportunities for personal contacts between researchers, investors, companies and government decision-makers.
The forum will continue to bring together the academic, business and public sectors in order to create more efficient and more successful collaborations not only at a national, but also at an international level.